NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
4.140
+0.090 (2.22%)
At close: Jun 5, 2026, 4:00 PM EDT
4.081
-0.059 (-1.43%)
After-hours: Jun 5, 2026, 7:58 PM EDT
NRx Pharmaceuticals Revenue
NRx Pharmaceuticals had revenue of $1.07M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $2.29M. In the year 2025, NRx Pharmaceuticals had annual revenue of $1.23M.
Revenue (ttm)
$2.29M
Revenue Growth
n/a
P/S Ratio
65.35
Revenue / Employee
$79,069
Employees
29
Market Cap
149.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| Oramed Pharmaceuticals | 2.00M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
| Connect Biopharma Holdings | 233.00K |
NRXP News
- 14 hours ago - NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - GlobeNewsWire
- 1 day ago - NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option - GlobeNewsWire
- 2 days ago - NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50 - TheFly
- 2 days ago - NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 3 days ago - NRx Pharmaceuticals announces common stock offering, no amount given - TheFly
- 3 days ago - NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 8 days ago - NRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026 - GlobeNewsWire
- 9 days ago - NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System - GlobeNewsWire